A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis
Phase of Trial: Phase II
Latest Information Update: 28 May 2018
At a glance
- Drugs NP 213 (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Taro Pharmaceuticals USA
- 17 May 2018 Planned End Date changed from 1 May 2018 to 1 Jun 2018.
- 17 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 May 2018.
- 17 May 2018 According to a Taro Pharmaceuticals Inc media release, this trial did not meet the main goal and the study data is being analysed to determine next course of action in the program.